Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dinutuximab and Sargramostim with Chemotherapy in High-Risk Neuroblastoma
NCT03786783Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2019
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of dinutuximab, sargramostim in neuroblastoma, ganglioneuroblastoma (GNB), sponsored by National Cancer Institute. Started Mar 2019; status: completed.
02
Drugs
dinutuximabsargramostim
03
Conditions
neuroblastomaganglioneuroblastoma (GNB)
Beyond the preview
Go deeper on NCT03786783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03786783.